A5034086278- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- Cancer-related gene regulation
- RNA and protein synthesis mechanisms
- Nanoplatforms for cancer theranostics
- RNA Research and Splicing
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Epigenetics and DNA Methylation
- Acute Lymphoblastic Leukemia research
- Extracellular vesicles in disease
- RNA Interference and Gene Delivery
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Ferroptosis and cancer prognosis
- Chronic Lymphocytic Leukemia Research
- MicroRNA in disease regulation
- Advanced biosensing and bioanalysis techniques
Sun Yat-sen University
2021-2024
China Pharmaceutical University
2018-2021
State Key Laboratory of Natural Medicine
2020-2021
N6-methyladenosine (m6A) modification is critical for mRNA splicing, nuclear export, stability and translation. Fat mass obesity-associated protein (FTO), the first identified m6A demethylase, cancer progression. Herein, we developed small-molecule inhibitors of FTO by virtual screening, structural optimization, bioassay. As a result, two namely 18077 18097 were identified, which can selectively inhibit demethylase activity FTO. Specifically, bound to active site then inhibited cell cycle...
Abstract Angiogenesis is hijacked by cancer to support tumor growth. RNA modifications such as N6-methyladenosine (m6A) can regulate several aspects of cancer, including angiogenesis. Here, we find that m6A triggers angiogenesis in lung upregulating VEGFA, a central regulator neovasculature and blood vessel m6A-sequencing functional studies confirmed modification the 5′UTR (untranslated region) VEGFA positively regulates its translation. Specifically, methylation internal ribosome entry site...
Abstract N6-methyladenosine (m6A) is the most prevalent RNA modification in eukaryotic mRNAs. Currently available detection methods for locus-specific m6A marks rely on RT-qPCR, radioactive methods, or high-throughput sequencing. Here, we develop a non-qPCR, ultrasensitive, isothermal, and naked-eye visible method based rolling circle amplification (RCA) loop-mediated isothermal (LAMP), named m6A-Rol-LAMP, to verify putative sites transcripts obtained from data. When padlock probes hybridize...
Abstract N 6 -methyladenosine (m A) and its associated reader protein insulin like growth factor 2 mRNA binding 3 (IGF2BP3) are involved in tumor initiation progression via regulating RNA metabolism. This study aims to investigate the biological function clinical significance of IGF2BP3 gastric cancer (GC). The was evaluated using related databases tissues. role molecular mechanism GC were investigated by multi-omics analysis including Ribosome sequence (Ribo-seq), (RNA-seq) m A A-seq)...
As an efficient tumor immunotherapy, PD-1 antibody has been gradually used in clinical treatment, but the low response rate and excessive immune limit its extensive application.Herein, a therapeutic regime for reinvigoration activation of microenvironment is introduced to improve anti-tumor effect antibody. To comprehensively immunotherapy reduce response, biomimetic cascade targeting nanosystem, siRNA@PLOV, which was fused by photothermal sensitive liposomes (PTSLs) attenuated Salmonella...
<title>Abstract</title> RNA modification recognition proteins are crucial in cancer development and progression. Among all modification-related (RMRPs), Weighted Gene Co-expression Network Analysis (WGCNA), along with comprehensive thorough analysis, suggests that NAT10, the sole known writer of N4-acetylcysteine (ac4C), as a critical regulatory protein associated colorectal (CRC) NAT10 facilitates malignancy DNA damage repair CRC cells via its ac4C transferase activity regulation Peter Pan...
Abstract Primary cilia are microtubule‐based organelles that function as cellular antennae to address multiple metabolic and extracellular cues. The past decade has seen significant advances in understanding the pro‐tumorigenic role of N 6 ‐methyladenosine (m A) modification tumorigenesis. Nevertheless, whether m A modulates dynamics during cancer progression remains unclear. Here, results show methyltransferase METTL3 regulates length cells via HDAC6‐dependent deacetylation axonemal...
Although EML4-ALK transforming fusion gene is represented in only 8% of non-small cell lung cancer (NSCLC) cases, its expression partly responsive for the failure current NSCLC treatments. Preventing secondary mutation ALK protein through direct manipulation could overcome drug resistance. Method: In this study, we developed a gold nanoshell (HAuNs) carrier delivery and selective photo-thermal release genes that target microRNA-301 NSCLC. Additionally, densely-coated adsorbed high amounts...
A polyelectrolyte microcapsule-based layer-by-layer (LbL) technique has been widely used as a multifunctional vehicle for combined tumor therapy. Meanwhile, with the rapid development of tumour therapy, challenge designing drug delivery system attracted much more attention. Herein, we developed new type microcapsule (MC) called MPA@siRNA@DOX@MC, which conjugated siRNA and DOX well ICG-Der-02 (MPA) by electrostatic absorption. MPA indocyanine green (ICG) fluorescence dye, exhibiting high...
<p>The detailed procedures of methods and eight figures are attached in supplementary.</p>
<div>Abstract<p>Angiogenesis is hijacked by cancer to support tumor growth. RNA modifications such as N6-methyladenosine (m6A) can regulate several aspects of cancer, including angiogenesis. Here, we find that m6A triggers angiogenesis in lung upregulating vascular endothelial growth factor-A (VEGFA), a central regulator neovasculature and blood vessel m6A-sequencing functional studies confirmed modification the 5’UTR VEGFA positively regulates its translation. Specifically,...
<p>The detailed procedures of methods and eight figures are attached in supplementary.</p>
<p>The detailed procedures of methods and eight figures are attached in supplementary.</p>
<p>The detailed procedures of methods and eight figures are attached in supplementary.</p>
<div>Abstract<p>Angiogenesis is hijacked by cancer to support tumor growth. RNA modifications such as <i>N6</i>-methyladenosine (m<sup>6</sup>A) can regulate several aspects of cancer, including angiogenesis. Here, we find that m6A triggers angiogenesis in lung upregulating VEGFA, a central regulator neovasculature and blood vessel m<sup>6</sup>A-sequencing functional studies confirmed m<sup>6</sup>A modification the 5′UTR...
<div>Abstract<p>Angiogenesis is hijacked by cancer to support tumor growth. RNA modifications such as <i>N6</i>-methyladenosine (m<sup>6</sup>A) can regulate several aspects of cancer, including angiogenesis. Here, we find that m6A triggers angiogenesis in lung upregulating VEGFA, a central regulator neovasculature and blood vessel m<sup>6</sup>A-sequencing functional studies confirmed m<sup>6</sup>A modification the 5′UTR...